4-sec-Butyl-2-fluoro-biphenyl | 55305-23-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-sec-Butyl-2-fluoro-biphenyl
• 英文别名: 4-Butan-2-yl-2-fluoro-1-phenylbenzene
• CAS: 55305-23-2
• 化学式: C₁₆H₁₇F
• 分子量: 228.309
• InChiKey: BYMLOFSFYXLOQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-Fluoro-4-((Z)-1-methyl-propenyl)-biphenyl 在 palladium on activated charcoal 氢气 作用下， 以 乙酸乙酯 为溶剂， 生成 4-sec-Butyl-2-fluoro-biphenyl
  参考文献：
  名称：

  FR2231393

  摘要：

  公开号：

文献信息

• Selective Cobalt-Catalyzed Reduction of Terminal Alkenes and Alkynes Using (EtO)₂Si(Me)H as a Stoichiometric Reductant
  作者：Balaram Raya、Souvagya Biswas、T. V. RajanBabu

  DOI：10.1021/acscatal.6b02272

  日期：2016.9.2

  the hydrogen source, is best run at ambient temperature in toluene and is highly selective for the reduction of simple unsubstituted 1-alkenes and the terminal double bonds in 1,3- and 1,4-dienes, β-vinyl ketones, and silyloxy dienes. The reaction is tolerant of various functional groups such as bromide, alcohol, amine, carbonyl, di- or trisubstituted double bonds, and water. Highly selective reduction

  在尝试实现β-乙烯基三甲基甲硅烷基烯醇醚的共催化氢化硅烷化时，我们发现，取决于硅烷，溶剂和还原钴催化剂的生成方法，烯烃可以高效，选择性地还原或氢化硅烷化取得成就。本文讨论了这种还原反应，尽管在该领域有大量的研究活动，但尚未见报道。该反应使用由2当量的NaEt 3 BH活化的空气稳定的[2,6-双（芳基吡啶基吡啶）吡啶] CoCl 2作为催化剂（0.001-0.05当量）和（EtO）2SiMeH作为氢源，最好在室温下在甲苯中运行，并且对还原简单的未取代的1-烯烃和1,3-和1,4-二烯，β-乙烯基酮和甲硅烷氧基二烯。该反应耐受各种官能团，例如溴化物，醇，胺，羰基，二或三取代的双键和水。通过使用化学计量的硅烷，可以将末端炔烃高度选择性地还原为烯烃或烷烃。初步的机理研究表明，该反应在硅烷中是化学计量的，产物中的两个氢均来自硅烷。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT D'UNE INFLAMMATION
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018115984A1

  公开（公告）日：2018-06-28

  The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.

  本公开提供了化合物I的结构或其药用可接受的盐，以及其多晶型、对映体、立体异构体、溶剂合物和水合物。这些化合物可以制备成药物组合物。药物组合物可以制备成口服、静脉注射、喷雾、注射、含片、溶液、糖浆、小包装、经皮给药或注射的药物。这些组合物可用于治疗炎症或其相关并发症。
• ADAM10 and its Uses Related to Infection
  申请人：Rubin Donald H.

  公开号：US20090220514A1

  公开（公告）日：2009-09-03

  The present invention relates to a protein, ADAM10, ADAM10 nucleic acid sequences and ADAM10 proteins encoded by these sequences that are involved in infection by one or more pathogen such as a virus, a parasite, a bacteria or a fungus or are otherwise associated with the life cycle of a pathogen.

  本发明涉及一种蛋白质ADAM10，ADAM10核酸序列和由这些序列编码的ADAM10蛋白质，它们参与感染一种或多种病原体，例如病毒、寄生虫、细菌或真菌，或与病原体的生命周期有关。
• Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors
  申请人：Wood Alastair J.J.

  公开号：US20120270884A1

  公开（公告）日：2012-10-25

  The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-IO. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more MMPs or ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm. The invention also comprises methods of treating aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm utilizing the compounds of the invention in conjunction with inhibitors of angiotensin II, including angiotensin II receptor blockers and angiotensin converting enzyme inhibitors, and cyclophillin inhibitors.

  本发明提供了通过抑制MMPs和ADAM-IO治疗动脉瘤扩张、血管壁弱点，尤其是腹主动脉瘤和胸主动脉瘤的方法。这些化合物在体外研究MMPs和ADAM-10（及其抑制）在生物过程中的作用方面是有用的。本发明还包括药物组合物，其包括一种或多种MMPs或ADAM-10抑制剂和药学上可接受的载体。这样的组合物对于治疗动脉瘤扩张或血管壁弱点，例如腹主动脉瘤和胸主动脉瘤是有用的。本发明还包括使用本发明的化合物与血管紧张素II的抑制剂（包括血管紧张素II受体拮抗剂和血管紧张素转换酶抑制剂）以及环肽酶抑制剂联合治疗动脉瘤扩张或血管壁弱点，例如腹主动脉瘤和胸主动脉瘤的方法。
• FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES
  申请人：Milne Jill C.

  公开号：US20130065934A1

  公开（公告）日：2013-03-14

  The invention relates to fatty acid COX inhibitor derivatives; compositions comprising an effective amount of a fatty acid COX inhibitor derivative; and methods for treating or preventing a metabolic, autoimmune, inflammatory, or neurodegenerative disorder comprising the administration of an effective amount of a fatty acid COX inhibitor derivative.

  本发明涉及脂肪酸COX抑制剂衍生物；包含有效量脂肪酸COX抑制剂衍生物的组合物；以及治疗或预防代谢性、自身免疫性、炎症性或神经退行性疾病的方法，其中包括给予有效量的脂肪酸COX抑制剂衍生物。